Work

Reply to “Silent Progression or Bout Onset Progressive Multiple Sclerosis?”

Year: 2019

Type: letter

Abstract: B.A.C.C. reports personal fees for consulting from Abbvie, Akili, Biogen, EMD Serono, GeNeuro, Novartis, Sanofi Genzyme and TG Therapeutics, outside the submitted work. S.L.H. reports personal fees from Neurona (board of trustees), Symbiotix (scientific advisory board [SAB]), Annexon (SAB), Bionure (SAB), Molecular Stethoscope (SAB), and Alector (SAB) and nonfinancial support from F. Hoffmann-La Roche (travel reimbursement and writing assistance for CD20-related meetings and presentations), outside the submitted work.

Source: Annals of Neurology

DOI: 10.1002/ana.25536

Authors: Bruce A. C. Cree, Stephen L. Hauser

Institutions: University of California, San Francisco, University of California San Francisco Medical Center

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2953635750

Cites: 3

Cited by: 4

Related to: 10